Aspirate from human stented native coronary arteries vs. saphenous vein grafts: More endothelin but less particulate debris

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 8, 2013, Pages

  Kleinbongard, Petra ^a   Baars, Theodor ^a   Möhlenkamp, Stefan ^b   Kahlert, Philipp ^a   Erbel, Raimund ^a   Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Krankenhaus Bethanien   (Germany)

Author keywords

Coronary disease; Ischemia; Native coronary artery; Saphenous vein graft; Vasoconstriction

Indexed keywords

ACETYLSALICYLIC ACID; CATECHOLAMINE; CLOPIDOGREL; ENDOTHELIN; HEPARIN; SEROTONIN; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASPIRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; HUMAN; INTRAVASCULAR ULTRASOUND; LOADING DRUG DOSE; LUNG EMBOLISM; MALE; METAL IMPLANTATION; PARTICULATE MATTER; PRIORITY JOURNAL; PROTEIN SECRETION; SAPHENOUS VEIN GRAFT; SELF EXPANDING STENT; STABLE ANGINA PECTORIS; VASCULAR GUIDE WIRE; VASCULAR STENT;

CORONARY DISEASE; ISCHEMIA; NATIVE CORONARY ARTERY; SAPHENOUS VEIN GRAFT; VASOCONSTRICTION;

AGED; ANGINA, STABLE; ANIMALS; CORONARY STENOSIS; ENDOTHELINS; EPINEPHRINE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MESENTERIC ARTERIES; MIDDLE AGED; NOREPINEPHRINE; RATS; SAPHENOUS VEIN; SEROTONIN; STENTS; THROMBOPLASTIN; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION;

EID: 84885669315     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00358.2013     Document Type: Article

References (42)

1. Adlbrecht C, Bonderman D, Plass C, Jakowitsch J, Beran G, Sperker W, Siostrzonek P, Glogar D, Maurer G, Lang IM. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 97: 642-649, 2007.
2. Baars T, Kleinbongard P, Böse D, Konorza T, Möhlenkamp S, Hippler J, Erbel R, Heusch G. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. Basic Res Cardiol 107: 303, 2012.
3. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105: 1285-1290, 2002.
4. Bauer J, Dau C, Cavarape A, Schaefer F, Ehmke H, Parekh N. ANG IIand TxA2-induced mesenteric vasoconstriction in rats is mediated by separate cell signaling pathways. Am J Physiol Heart Circ Physiol 277: H1-H7, 1999.
5. Bax WA, Renzenbrink GJ, van der Linden EA, Zijlstra FJ, van Heuven-Nolsen D, Fekkes D, Bos E, Saxena PR. Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary artery. A role for additional 5-hydroxytryptamine receptor antagonism against coronary vasospasm? Circulation 89: 623-629, 1994.
6. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 99: 2794-2800, 2002.
7. Chester AH, Allen SP, Tadjkarimi S, Yacoub MH. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 87: 874-880, 1993.
8. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927, 2001.
9. El-Jack SS, Suwatchai P, Stewart JT, Ruygrok PN, Ormiston JA, West T, Webster MW. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. J Interv Cardiol 20: 474-480, 2007.
10. Frisbee JC, Goodwill AG, Stapleton PA, Frisbee SJ, D'Audiffret AC. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genomics 42: 331-341, 2010.
11. Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM, Chilian WM, Zhang C. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 27: 1269-1275, 2007.
12. Grube E, Gerckens U, Yeung AC, Rowold S, Kirchhof N, Sedgewick J, Yadav JS, Stertzer S. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 104: 2436-2441, 2001.
13. Haude M, Caspari G, Baumgart D, Brennecke R, Meyer J, Erbel R. Comparison of myocardial perfusion reserve before and after coronary balloon predilation and after stent implantation in patients with postangioplasty restenosis. Circulation 94: 286-297, 1996.
14. Heusch G, Kleinbongard P, Boese D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation 120: 1822-1836, 2009.
15. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and-2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 271: 12042-12048, 1996.
16. Kleinbongard P, Boese D, Baars T, Moehlenkamp S, Konorza T, Schoener S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108: 344-352, 2011.
17. Kleinbongard P, Boese D, Konorza T, Steinhilber F, Moehlenkamp S, Eggebrecht H, Baars T, Degen H, Haude M, Levkau B, Erbel R, Heusch G. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. Basic Res Cardiol 106: 681-689, 2011.
18. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127: 295-314, 2010.
19. Kleinbongard P, Konorza T, Boese D, Baars T, Haude M, Erbel R, Heusch G. Lessons from human coronary aspirate. J Mol Cell Cardiol 52: 890-896, 2012.
20. Leborgne L, Cheneau E, Pichard A, Ajani A, Pakala R, Yazdi H, Satler L, Kent K, Suddath WO, Pinnow E, CAnos D, Waksman R. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. Am Heart J 146: 501-506, 2003.
21. Leineweber K, Boese D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 47: 981-986, 2006.
22. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124: e574-e651, 2011.
23. Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokineand innate-immunity-related inflammatory mechanisms. Innate Immun 14: 63-87, 2008.
24. Lüscher T, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440, 2000.
25. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46: 986-993, 2005.
26. Merkus D, Brzezinska AK, Zhang C, Saito S, Chilian WM. Cardiac myocytes control release of endothelin-1 in coronary vasculature. Am J Physiol Heart Circ Physiol 288: H2088-H2092, 2005.
27. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37: 1478-1492, 2001.
28. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97: 916-931, 1998.
29. Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De BB, Wijns W, Barbato E. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 105: 333-338, 2010.
30. Niccoli G, Lanza GA, Shaw s Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M, Rebuzzi AG, Lüscher TF, Crea F. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 27: 1793-1798, 2006.
31. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372: 49-56, 1999.
32. Nishimura Y, Suzuki A. Enhanced contractile responses mediated by different 5-HT receptor subtypes in basilar arteries, superior mesenteric arteries and thoracic aortas from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22: S99-S101, 1995.
33. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 165: 1605-1611, 2000.
34. Pregowski J, Tyczynski P, Mintz GS, Kim SW, Witkowski A, Waksman R, Pichard A, Satler L, Kent K, Kruk M, Bieganski S, Ohlmann P, Weissman NJ. Incidence and clinical correlates of ruptured plaques in saphenous vein grafts. An intravascular ultrasound study. J Am Coll Cardiol 45: 1974-1979, 2005.
35. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, Virmani R. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond) 114: 211-220, 2008.
36. Shirai N, Naruko T, Ohsawa M, Ikura Y, Sugama Y, Hirayama M, Kitabayashi C, Ehara S, Inoue T, Itoh A, Haze K, Tanzawa K, Yoshiyama M, Yoshikawa J, Ueda M. Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. J Hypertens 24: 711-721, 2006.
37. Silva JA, White CJ, Collins TJ, Ramee SR. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. Am Heart J 136: 156-163, 1998.
38. Sorop O, Merkus D, de B, V, Houweling B, Pistea A, McFalls EO, Boomsma F, van Beusekom HM, Van der Giessen WJ, VanBavel E, Duncker DJ. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ Res 102: 795-803, 2008.
39. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108: 548-553, 2003.
40. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Gabriel SP, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de LJ, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ.Third universal definition of myocardial infarction. Eur Heart J 33: 2551-2567, 2012.
41. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings TIMI Srtudy Group. N Engl J Med 312: 932-936, 1985.
42. Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of inreased vasoreactivity of the culprit lesion in unstable angina. Circulation 91: 941-947, 1995.